Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morschhauser

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 5